Details of the Drug Combinations

General Information of This Drug (ID: DMTOI7S)

Drug Name

ARRY-520 DMTOI7S

Synonyms

Filanesib; ARRY-520; 885060-09-3; UNII-8A49OSO368; Arry520; CHEMBL2347655; ARRY 520 trifluoroacetate; 8A49OSO368; ARRY 520; (2S)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3(2H)-carboxamide; Filanesib [INN]; Filanesib [USAN:INN]; C20H22F2N4O2S; ARRY-520; Filanesib; 1385020-40-5; Filanesib(ARRY-520); SCHEMBL368043; DTXSID50237086; EX-A678; BCP07442; ZINC43204022; 3452AH; BDBM50431893; AKOS030526964; SB19209; RL05514; CS-0867; NCGC00381751-02; NCGC00381751-04

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ARRY-520 + Ruxolitinib	DCLBFSC	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[3]
------------------------------------------------------------------------------------

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Carfilzomib + ARRY-520	DCIEV82	Carfilzomib	Plasma Cell Leukemia	[4]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT01989325) A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma. U.S. National Institutes of Health.
3	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
4	ClinicalTrials.gov (NCT01372540) Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia